Process Analytical Tools To Control Polymorphism and Particle Size in Batch Crystallization Processes

被引:27
作者
Hansen, Thomas B. [1 ]
Simone, Elena [2 ,4 ]
Nagy, Zoltan [3 ,4 ]
Qu, Haiyan [1 ]
机构
[1] Univ Southern Denmark, Dept Chem Engn Biotechnol & Environm Technol, Campusvej 55, DK-5230 Odense, Denmark
[2] Univ Leeds, Sch Food Sci & Nutr, Leeds LS2 9JT, W Yorkshire, England
[3] Purdue Univ, Sch Chem Engn, W Lafayette, IN 47907 USA
[4] Loughborough Univ, Chem Engn Dept, Loughborough LE11 3TU, Leics, England
基金
欧洲研究理事会;
关键词
DIRECT NUCLEATION CONTROL; ACTIVE PHARMACEUTICAL INGREDIENT; CONTINUOUS MIXED SUSPENSION; ANTISOLVENT CRYSTALLIZATION; FEEDBACK-CONTROL; SUPERSATURATION CONTROL; SYSTEMATIC DESIGN; FINES REMOVAL; ATR-FTIR; DISSOLUTION;
D O I
10.1021/acs.oprd.7b00087
中图分类号
O69 [应用化学];
学科分类号
081704 ;
摘要
In this work, process analytical technology (PAT) based approaches for controlling the polymorphism and crystal size of a nonsteroidal anti-inflammatory drug (piroxicam) during batch cooling crystallization has been investigated. Previously obtained results regarding the crystallization behavior of the different polymorphs of piroxicam in a small-scale" (100 mL) crystallizer have been used to design and to initiate the control approach described in this paper. The results of the present work demonstrated the challenge of reproducing the crystallization process with respect to the product polymorphism at different scales. The solute concentration has been proved to be a critical parameter in determining the polymorphism of piroxicam in the small-scale crystallization experiments; however, the same operation parameters could not yield the same polyniorph in the crystallization in 2 L crystallizers. Both direct nucleation control (DNC) and supersatiiration control (SSC) have been proven to be effective at controlling the polymorphism of piroxicam in seeded cooling,crystallization; furthermore, applying DNC also improved the particulate properties (larger crystal size).
引用
收藏
页码:855 / 865
页数:11
相关论文
共 28 条
[1]   Seeded Batch Cooling Crystallization with Temperature Cycling for the Control of Size Uniformity and Polymorphic Purity of Sulfathiazole Crystals [J].
Abu Bakar, Mohd R. ;
Nagy, Zoltan K. ;
Rielly, Chris D. .
ORGANIC PROCESS RESEARCH & DEVELOPMENT, 2009, 13 (06) :1343-1356
[2]   The Impact of Direct Nucleation Control on Crystal Size Distribution in Pharmaceutical Crystallization Processes [J].
Abu Bakar, Mohd R. ;
Nagy, Zoltan K. ;
Saleemi, Ali N. ;
Rielly, Chris D. .
CRYSTAL GROWTH & DESIGN, 2009, 9 (03) :1378-1384
[3]   Crystal engineering of active pharmaceutical ingredients to improve solubility and dissolution rates [J].
Blagden, N. ;
de Matas, M. ;
Gavan, P. T. ;
York, P. .
ADVANCED DRUG DELIVERY REVIEWS, 2007, 59 (07) :617-630
[4]   PIROXICAM MONOHYDRATE - A ZWITTERIONIC FORM, C15H13N3O4S.H2O [J].
BORDNER, J ;
RICHARDS, JA ;
WEEKS, P ;
WHIPPLE, EB .
ACTA CRYSTALLOGRAPHICA SECTION C-CRYSTAL STRUCTURE COMMUNICATIONS, 1984, 40 (JUN) :989-990
[5]   Quantitative analysis of piroxicam polymorphs pharmaceutical mixtures by hyperspectral imaging and chemometrics [J].
de Carvalho Rocha, Werickson Fortunato ;
Sabin, Guilherme Post ;
Marco, Paulo Henrique ;
Poppi, Ronei Jesus .
CHEMOMETRICS AND INTELLIGENT LABORATORY SYSTEMS, 2011, 106 (02) :198-204
[6]   Novel, Calibration-Free Strategies for Supersaturation Control in Antisolvent Crystallization Processes [J].
Duffy, D. ;
Barrett, M. ;
Glennon, B. .
CRYSTAL GROWTH & DESIGN, 2013, 13 (08) :3321-3332
[7]   Formation of Piroxicam Polymorphism in Solution Crystallization: Effect and Interplay of Operation Parameters [J].
Hansen, Thomas B. ;
Qu, Haiyan .
CRYSTAL GROWTH & DESIGN, 2015, 15 (09) :4694-4700
[8]   Microwave Assisted Direct Nucleation Control for Batch Crystallization: Crystal Size Control with Reduced Batch Time [J].
Kacker, Rohit ;
Salvador, Pedro M. ;
Sturm, Guido S. J. ;
Stefanidis, Georgios D. ;
Lakerveld, Richard ;
Nagy, Zoltan K. ;
Kramer, Herman J. M. .
CRYSTAL GROWTH & DESIGN, 2016, 16 (01) :440-446
[10]   Monitoring and feedback control of supersaturation using ATR-FTIR to produce an active pharmaceutical ingredient of a desired crystal size [J].
Liotta, V ;
Sabesan, V .
ORGANIC PROCESS RESEARCH & DEVELOPMENT, 2004, 8 (03) :488-494